CLDI (STOCKS)
Calidi Biotherapeutics, Inc.
$0.164900
+0.012900 (+8.49%)
Prev close: $0.152000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Eric E. Poma
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3.25M
- Employees
- 28
- P/E (TTM)
- -0.03
- P/B (TTM)
- 0.36
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
3
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.43 | $-1.63 | +1.1979 | +73.59% |
|
Sep 2025 (Q3)
|
$-2.21 | $-1.71 | -0.4964 | -28.97% |
|
Jun 2025 (Q2)
|
$-1.99 | $-2.00 | +0.0051 | +0.26% |
|
Mar 2025 (Q1)
|
$-2.16 | $-1.81 | -0.3485 | -19.24% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $272.00K |
| Operating Expenses | $19.37M |
| Selling, General, and Administrative Expenses | $9.47M |
| Depreciation and Amortization | $1.68M |
| Research and Development | $9.90M |
| Operating Income/Loss | -$19.37M |
| Income/Loss From Continuing Operations After Tax | -$19.11M |
| Income/Loss From Continuing Operations Before Tax | -$19.09M |
| Income Tax Expense/Benefit | $16.00K |
| Net Income/Loss | -$19.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$35.00K |
| Net Income/Loss Attributable To Parent | -$19.03M |
| Net Income/Loss Available To Common Stockholders, Basic | -$25.01M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $5.98M |
| Preferred Stock Dividends And Other Adjustments | $5.98M |
| Basic Earnings Per Share | -$4.18 |
| Diluted Earnings Per Share | -$4.18 |
| Basic Average Shares | 10,316,724 |
| Diluted Average Shares | 10,316,724 |
| Assets | $9.59M |
| Current Assets | $7.35M |
| Noncurrent Assets | $2.24M |
| Fixed Assets | $758.00K |
| Other Non-current Assets | $1.48M |
| Liabilities | $4.66M |
| Current Liabilities | $3.84M |
| Noncurrent Liabilities | $820.00K |
| Long-term Debt | $600.00K |
| Other Non-current Liabilities | $220.00K |
| Equity | $4.94M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $4.94M |
| Liabilities And Equity | $9.59M |
| Net Cash Flow From Operating Activities | -$18.28M |
| Net Cash Flow From Operating Activities, Continuing | -$18.28M |
| Net Cash Flow From Investing Activities | -$168.00K |
| Net Cash Flow From Investing Activities, Continuing | -$168.00K |
| Net Cash Flow From Financing Activities | $14.51M |
| Net Cash Flow From Financing Activities, Continuing | $14.51M |
| Net Cash Flow | -$3.92M |
| Net Cash Flow, Continuing | -$3.94M |
| Comprehensive Income/Loss | -$19.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$35.00K |
| Comprehensive Income/Loss Attributable To Parent | -$19.02M |
| Other Comprehensive Income/Loss | -$9.00K |